Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through studyMarc Ferrante, Luciana Teixeira de Campos, Geert D’Haens et al.|The Lancet|2024Cited by 107
Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South ChinaCheng Fang, Jie Chen, Minhu Chen et al.|癌症：英文版|2017Cited by 49
Exploration of the Exact Prognostic Significance of Lymphatic Metastasis in Jejunoileal Neuroendocrine TumorsLuohai Chen, Jie Chen, Yunda Song et al.|Annals of Surgical Oncology|2018Cited by 31
S1429 Efficacy of Guselkumab in Moderately to Severely Active Crohn’s Disease According to Induction Clinical Response Status: Week 48 Results from the GALAXI 2 & 3 Phase 3 TrialsAnita Afzali, Geert D’Haens, Julián Panés et al.|The American Journal of Gastroenterology|2024Cited by 0